Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.
Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS). Four anticoagulant agents are currently commercially available for ACS, namely unfractionated heparin (UFH), enoxaparin, bivalirudin and fondaparinux. We describe the advantages of fondaparinux and the reasons that have hampered its uptake into routine management of ACS. Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and UFH. Two pivotal studies have demonstrated the efficacy of fondaparinux as an anticoagulant in the setting of ACS, namely OASIS-5 in non-ST elevation ACS, and OASIS-6 in ST elevation myocardial infarction (MI). In OASIS-5, fondaparinux was shown to be noninferior to enoxaparin in terms of death, MI or refractory ischemia at 9 days. Furthermore, a 50% reduction in bleeding complications was obtained with fondaparinux vs enoxaparin, leading to a risk reduction for death. In OASIS-6, fondaparinux was shown to be superior to the comparator (UFH or placebo). European and North American guidelines give fondaparinux a Grade 1A and 1B recommendation respectively, but uptake of fondaparinux in routine practice has been slow. We explore reasons for this, such as prevailing doubts about the efficacy of fondaparinux in the setting of angioplasty, the problem of catheter thrombosis, and the lack of antidote in case of bleeding complications. With the exception of primary angioplasty, fondaparinux is as effective as enoxaparin or UFH, but is also associated with a considerable reduction in bleeding complications, and thus, an undeniable net clinical benefit.
Schiele
François
F
Department of Cardiology, University Hospital Jean-Minjoz, Besançon, France. francois.schiele@univ-fcomte.fr
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D002404:Catheterization / Q000009:adverse effects; D017984:Enoxaparin / Q000627:therapeutic use; D000077425:Fondaparinux; D006629:Hirudins; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D011134:Polysaccharides / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology
D000925:Anticoagulants; D017984:Enoxaparin; D006629:Hirudins; D010446:Peptide Fragments; D011134:Polysaccharides; D011994:Recombinant Proteins; D000077425:Fondaparinux; C074619:bivalirudin
Circulation. 1999 Oct 12;100(15):1593-601
10517729
J Am Coll Cardiol. 2006 Oct 3;48(7):1346-54
17010793
Eur Heart J. 2008 Dec;29(23):2909-45
19004841
N Engl J Med. 2001 Nov 1;345(18):1305-10
11794149
Lancet. 2008 May 10;371(9624):1559-61
18468530
Hematology. 2004 Oct-Dec;9(5-6):317-32
15763970
J Am Coll Cardiol. 2007 Oct 30;50(18):1742-51
17964037
Clin Appl Thromb Hemost. 2008 Jan;14(1):97-8
18160576
Eur Heart J. 2009 Jun;30(12):1457-66
19351691
N Engl J Med. 2006 Apr 6;354(14):1464-76
16537663
J Thromb Haemost. 2003 Jan;1(1):69-73
12871541
Chest. 2008 Jun;133(6 Suppl):670S-707S
18574276
Am Heart J. 2010 Feb;159(2):190-8
20152216
N Engl J Med. 2006 Apr 6;354(14):1477-88
16537665
Thromb Haemost. 1999 Feb;81(2):214-20
10063994
JAMA. 2004 Jul 7;292(1):45-54
15238590
Eur Heart J. 2007 Jul;28(13):1598-660
17569677
Chest. 2008 Jun;133(6 Suppl):708S-775S
18574277
N Engl J Med. 2008 May 22;358(21):2218-30
18499566
Circulation. 2008 Nov 11;118(20):2038-46
18955665
N Engl J Med. 2001 Nov 1;345(18):1298-304
11794148
N Engl J Med. 2008 Jun 5;358(23):2457-67
18434646
N Engl J Med. 2006 Nov 23;355(21):2203-16
17124018
Circulation. 2005 Mar 22;111(11):1390-7
15781750
Circulation. 2002 Nov 12;106(20):2550-4
12427650
J Am Coll Cardiol. 2007 Aug 14;50(7):e1-e157
17692738
Nature. 1999 Apr 1;398(6726):417-22
10201371
N Engl J Med. 1997 Aug 14;337(7):447-52
9250846
JAMA. 2006 Apr 5;295(13):1519-30
16537725
Eur Heart J. 2001 Sep;22(18):1716-24
11511121
Thromb Haemost. 2008 Oct;100(4):693-8
18841294
Lancet. 2008 Aug 16;372(9638):532-3; author reply 533-4
18707977